Biopharmaceuticals directed against tumor necrosis factor-alpha, integrins, interleukins, interferons and their receptors have become key agents for the management of inflammatory diseases in the fields of gastroenterology, rheumatology, dermatology and neurology. However, response to these treatments is far from optimal. Therapeutic failure has been attributed in part to inadequate serum conce...

While extensively used as drugs, small synthetic molecules have not yet been widely applied in the industry as affinity ligands for the purification of biopharmaceuticals. Yet, a substantial amount of published research indicates that synthetic ligands, such as triazine scaffolds, amino acids, and peptides show a great deal of promise for becoming the next generation affinity ligands for biosep...

Rather than focus on reducing prices for innovative biopharmaceuticals, insurers in the United States are changing methods of payment for oncologists in order to moderate the growth in cancer drug expenditures. The desire is for a better pattern of utilization and expenditures without adversely affecting incentives for research and development. After an overview of the contemporary discussions ...

Advances in human health biology and disease have opened up exciting new possibilities for potential new treatments and cures to meet patient needs. Our understanding of these molecular principles has revealed the existence of many regulatory molecules or proteins with medical significance. These proteins are produced naturally within the body only in minute quantities. Developments in recombin...